Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a Study Assessing the Safety and Efficacy of Intraputamenal Dopaminergic Stem Cell Transplants in Patients With Idiopathic Parkinson's Disease

NCT07106021 is registered in ClinicalTrials.gov with Kenai Therapeutics as lead sponsor.

NCT NCT07106021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07106021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a Study Assessing the Safety and Efficacy of Intraputamenal Dopaminergic Stem Cell Transplants in Patients With Idiopathic Parkinson's Disease
Lead sponsor
Kenai Therapeutics
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
July 17, 2025
Completion date
June 30, 2031
Enrollment
12 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic parkinson´s disease, parkinson's disease